COMPANY

Cadrenal Therapeutics

HQ: Ponte Vedra, FL source · cadrenal.com ↗ · Southeast

Our broader pipeline includes tecarfarin, a Phase 3-ready oral vitamin K antagonist for the treatment of patients with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral, clinical-stage Factor XIa inhibitor designed for use in acute hospital settings. From company website Source · Oct 13, 2026

Keywords: inhibitor

Location: Ponte Vedra, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Form D reports $8.84M in warrant exercise value (filed Jul 15, 2026); +2 other Form D filings in the last 12 months. SEC Form D 0001213900-26-078373 (Jul 15, 2026)
Evidence (3 events)
- Jul 15, 2026 · SEC Form D 0001213900-26-078373
  Name of Issuer: Cadrenal Therapeutics, Inc.; CIK: 1937993; Address: Ponte Vedra, FL; Submission type: D; Filing date: 2026-07-15; Industry Group: Biotechnology; Date of First Sale: 2026-06-30; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 8843849; Total Amount Sold: 8843849; Federal exemptions: 06b
- Apr 6, 2026 · SEC Form D 0001213900-26-040457
  Name of Issuer: Cadrenal Therapeutics, Inc.; CIK: 1937993; Address: Ponte Vedra, FL; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2026-04-01; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 7923235; Total Amount Sold: 7923235; Federal exemptions: 06b
- Dec 31, 2025 · SEC Form D 0001213900-25-127129
  Name of Issuer: Cadrenal Therapeutics, Inc.; CIK: 1937993; Address: Ponte Vedra, FL; Submission type: D; Filing date: 2025-12-31; Industry Group: Biotechnology; Date of First Sale: 2025-12-16; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4396329; Total Amount Sold: 4396329; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Mar 4, 2025 Partnership Partnership / licensing announced Mar 4, 2025. Source: SEC filing. source ↗

Funding

Last 2 years.

Mar 4, 2025 Partnership / licensing announced Mar 4, 2025. Source: SEC filing. source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-07-15 Raise Private raise (SEC Form D): $8.8M sold; issuer “Cadrenal Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
2026-04-06 Raise Private raise (SEC Form D): $7.9M sold; issuer “Cadrenal Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-12-31 Raise Private raise (SEC Form D): $4.4M sold; issuer “Cadrenal Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
2024-11-14 Raise Private raise (SEC Form D): $9.4M sold; issuer “Cadrenal Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗